Coherus Oncology Inc Revenue Growth Rates (CHRS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Coherus Oncology inc   (NASDAQ: CHRS)
 

CHRS's Revenue Growth by Quarter and Year

Coherus Oncology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CHRS/growth
https://api.csimarket.com/api/v1/companies/CHRS/fundamentals
https://api.csimarket.com/api/v1/companies/CHRS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CHRS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 14.27
2nd Quarter June 14.31
1st Quarter March 12.31
FY 40.89

CHRSs Annual Revenue
Coherus Oncology Inc 's Revenue in the fiscal year 2025 $ 42.17 millions
Coherus Oncology Inc 's Revenue in the fiscal year 2024 $ 266.96 millions
Coherus Oncology Inc 's Revenue in the fiscal year 2023 $ 257.24 millions
Coherus Oncology Inc 's Revenue in the fiscal year 2022 $ 211.04 millions
Coherus Oncology Inc 's Revenue in the fiscal year 2021 $ 326.55 millions




CHRS Revenue third quarter 2026 Y/Y Growth Comment
Coherus Oncology inc reported Revenue improvement of 23.37% year on year in the third quarter 2026, to $ 14.27 millions, this is lower than Coherus Oncology Inc 's recent average Revenue surge of 154.24%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue growth. While Coherus Oncology Inc ' s Revenue rise of 23.37% ranks overall at the positon no. 582 in the third quarter 2026.


CHRS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 23.37 %
2nd Quarter June 39.61 %
1st Quarter March 61.97 %
FY   -

Financial Statements
Coherus Oncology Inc 's third quarter 2026 Revenue $ 14.27 millions CHRS's Income Statement
Coherus Oncology Inc 's third quarter 2025 Revenue $ 11.57 millions Quarterly CHRS's Income Statement


CHRS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.25 %
2nd Quarter June 16.25 %
1st Quarter March -3.45 %
FY (Year on Year)   -


Back to CHRS Growth rate Comparisons >> Back to CHRS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #582

Revenue Y/Y Growth Statistics
High Average Low
3072.33 % 154.24 % -100 %
(Dec 31 2014)   (Dec 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #582
Revenue Y/Y Growth Statistics
High Average Low
3072.33 % 154.24 % -100 %
(Dec 31 2014)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Coherus Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1057.49 % 48.8 % -100 %
(Sep 30 2016)  


CHRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Coherus Oncology Inc disclosed decrease in Revenue from the second quarter by -0.25% to $ 14.27 millions, from $ 14.31 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Coherus Oncology Inc 's Revenue growth quarter on quarter, overall rank is 604.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #111
Overall #604
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #111
Overall #604
Revenue Q/Q Growth Statistics
High Average Low
1057.49 % 48.8 % -100 %
(Sep 30 2016)  


CHRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Coherus Oncology Inc disclosed decrease in Revenue from the second quarter by -0.25% to $ 14.27 millions, from $ 14.31 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Coherus Oncology Inc 's Revenue growth quarter on quarter, overall rank is 604.


Coherus Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 53.64
Y / Y Revenue Growth (TTM) -35.81 %
Year on Year Revenue Growth Overall Ranking # 3642
Seqeuential Revenue Change (TTM) 5.31 %
Seq. Revenue Growth (TTM) Overall Ranking # 3480


Cumulative Revenue growth Comment
Coherus Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Coherus Oncology Inc 's annual Revenue improvement would be -35.81% year on year to $54 millions.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3138 to 3642.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 506
Overall # 3642

Revenue TTM Y/Y Growth Statistics
High Average Low
1030.72 %
 93.84 %
-84.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 470
S&P 500 # 3480
Cumulative Revenue growth Comment
Coherus Oncology Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Coherus Oncology Inc 's annual Revenue drop would be -35.81% year on year to $54 millions.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3138 to 3642.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 506
Overall # 3642

Revenue TTM Y/Y Growth Statistics
High Average Low
1030.72 %
93.84 %
-84.2 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 470
S&P 500 # 3480




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CHRS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Biofrontera Inc 29.79%$ 29.794 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions


About Coherus Oncology Inc Revenue Growth Rates (CHRS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Coherus Oncology Inc (CIK 1512762).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-124572
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Coherus Oncology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.